Understanding the Current Rating
The 'Hold' rating assigned to Sudarshan Pharma Industries Ltd indicates a neutral stance for investors. It suggests that while the stock may not be an immediate buy, it is not a sell either. Investors are advised to maintain their current positions and monitor the company’s developments closely. This rating is based on a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals.
Quality Assessment
As of 02 September 2026, Sudarshan Pharma’s quality grade is assessed as average. The company operates within the Specialty Chemicals sector and is classified as a microcap entity. One notable concern is its high Debt to EBITDA ratio of 5.77 times, indicating a relatively low ability to service its debt obligations efficiently. This elevated leverage level can pose risks, especially in volatile market conditions or economic downturns.
Despite this, the company has demonstrated healthy long-term growth, with operating profit expanding at an annual rate of 47.89%. This robust growth trajectory reflects operational strength and effective management strategies, which partially offset concerns related to debt servicing.
Valuation Perspective
The valuation grade for Sudarshan Pharma is currently attractive. The company’s Return on Capital Employed (ROCE) stands at 10.8%, which is a reasonable return given its sector and size. Additionally, the Enterprise Value to Capital Employed ratio is a modest 2.8, suggesting that the stock is reasonably priced relative to the capital it employs.
Over the past year, the stock has generated a return of 17.82%, while profits have risen by 36%. This combination results in a Price/Earnings to Growth (PEG) ratio of 1.2, indicating that the stock’s price growth is broadly in line with its earnings growth, a sign of fair valuation for investors seeking balanced risk and reward.
Financial Trend Analysis
The financial trend for Sudarshan Pharma is currently flat, signalling stability but limited momentum in recent quarters. The company reported flat results in June 2026, with interest expenses for the nine months ending June 2026 rising by 35.09% to ₹22.02 crores. This increase in interest cost reflects the impact of the company’s leverage and could weigh on profitability if not managed carefully.
Nonetheless, the company’s consistent returns over the last three years are noteworthy. It has outperformed the BSE500 index in each of the last three annual periods, delivering steady returns to shareholders. This consistency is a positive indicator for investors looking for reliability in their portfolio holdings.
Technical Outlook
From a technical standpoint, Sudarshan Pharma exhibits a mildly bullish trend. The stock’s recent price movements show resilience, with a 6-month return of +41.11% and a year-to-date gain of +39.78%. The one-year return stands at +19.89%, reflecting solid performance relative to broader market indices.
Shorter-term trends are mixed, with a slight decline of 0.26% on the most recent trading day and a 1-week loss of 4.06%. However, the stock rebounded with a 1-month gain of 1.64% and a 3-month gain of 13.00%, indicating underlying strength despite short-term volatility.
Implications for Investors
For investors, the 'Hold' rating suggests maintaining existing positions rather than initiating new ones or exiting current holdings. The company’s attractive valuation and consistent returns provide a solid foundation, but the elevated debt levels and flat recent financial trends warrant caution.
Investors should monitor the company’s debt servicing capacity and interest expense trends closely, as these factors could influence future profitability and stock performance. Additionally, the mildly bullish technical indicators suggest potential for moderate upside, but with some risk of short-term fluctuations.
This week's disclosed pick, a Large Cap from NBFC, comes with precise Target Price and analysis. Check if you're positioned right for this opportunity!
- - Precise target price set
- - Weekly selection live
- - Position check opportunity
Summary of Key Metrics as of 02 September 2026
The latest data shows Sudarshan Pharma Industries Ltd with a Mojo Score of 58.0, reflecting its 'Hold' grade. The stock’s market capitalisation remains in the microcap category, operating within the Specialty Chemicals sector. The company’s financial health is characterised by a high Debt to EBITDA ratio of 5.77 times, signalling leverage concerns.
Operating profit growth remains strong at an annualised 47.89%, while interest expenses have increased by 35.09% over the last nine months. The ROCE of 10.8% and an Enterprise Value to Capital Employed ratio of 2.8 underpin the attractive valuation grade. The PEG ratio of 1.2 aligns the stock’s price with its earnings growth, supporting the neutral rating.
Stock returns have been robust, with a 6-month gain of 41.11%, year-to-date return of 39.78%, and a one-year return of 19.89%. These returns have consistently outperformed the BSE500 index over the past three years, highlighting the company’s ability to deliver shareholder value despite some financial headwinds.
Looking Ahead
Investors should weigh the company’s growth prospects against its debt servicing challenges. The flat financial trend and rising interest costs suggest a need for cautious optimism. The mildly bullish technical outlook offers some confidence in the stock’s price resilience, but volatility remains a factor to consider.
Overall, the 'Hold' rating reflects a balanced view, recognising Sudarshan Pharma Industries Ltd’s strengths in valuation and growth while acknowledging risks related to leverage and recent financial performance. Investors are advised to maintain their current holdings and stay alert to any material changes in the company’s fundamentals or market conditions.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
